BACKGROUND: Appreciation of the central role for arterial vasodilatation in the pathogenesis of hepatorenal syndrome (HRS) has led to routine use of vasoconstrictors in combination with albumin as a medical therapy for HRS. Various vasoconstrictors have been explored but the optimal approach for such therapies has not yet been established. AIMS: The purpose of this study was to examine the role of targeting an early and substantial increase in mean arterial pressure (MAP) in the management of type 1 HRS, a condition associated with very poor prognosis. METHODS: A total of 59 patients with type 1 HRS who received a combination therapy of vasoconstrictors and albumin were enrolled into a retrospective cohort study. Subjects having a substantial increase of more than 10 mmHg in MAP by day 3 after initiation of therapy were categorized as MAP responders and the rest as MAP non-responders. In addition, five patients were enrolled into a prospective pilot study in which a titration protocol of vasoconstrictors was followed to achieve early goal-directed therapy (EGDT). RESULTS: MAP responders achieved significantly higher incidence of treatment success or total response, less requirement of dialysis and more incidence of liver transplantation. More importantly, this response is associated with better short-term and long-term overall survival as well as transplant-free survival. The effectiveness of such an approach was further confirmed in the pilot study which followed an EGDT protocol. CONCLUSIONS: Using an early and substantial increase in MAP as a therapeutic target is associated with favorable clinical outcomes in the management of type 1 HRS.
BACKGROUND: Appreciation of the central role for arterial vasodilatation in the pathogenesis of hepatorenal syndrome (HRS) has led to routine use of vasoconstrictors in combination with albumin as a medical therapy for HRS. Various vasoconstrictors have been explored but the optimal approach for such therapies has not yet been established. AIMS: The purpose of this study was to examine the role of targeting an early and substantial increase in mean arterial pressure (MAP) in the management of type 1 HRS, a condition associated with very poor prognosis. METHODS: A total of 59 patients with type 1 HRS who received a combination therapy of vasoconstrictors and albumin were enrolled into a retrospective cohort study. Subjects having a substantial increase of more than 10 mmHg in MAP by day 3 after initiation of therapy were categorized as MAP responders and the rest as MAP non-responders. In addition, five patients were enrolled into a prospective pilot study in which a titration protocol of vasoconstrictors was followed to achieve early goal-directed therapy (EGDT). RESULTS: MAP responders achieved significantly higher incidence of treatment success or total response, less requirement of dialysis and more incidence of liver transplantation. More importantly, this response is associated with better short-term and long-term overall survival as well as transplant-free survival. The effectiveness of such an approach was further confirmed in the pilot study which followed an EGDT protocol. CONCLUSIONS: Using an early and substantial increase in MAP as a therapeutic target is associated with favorable clinical outcomes in the management of type 1 HRS.
Authors: Andreas Umgelter; Wolfgang Reindl; Michael Franzen; Cosima Lenhardt; Wolfgang Huber; Roland M Schmid Journal: Intensive Care Med Date: 2008-09-18 Impact factor: 17.440
Authors: Manu L N G Malbrain; Michael L Cheatham; Andrew Kirkpatrick; Michael Sugrue; Michael Parr; Jan De Waele; Zsolt Balogh; Ari Leppäniemi; Claudia Olvera; Rao Ivatury; Scott D'Amours; Julia Wendon; Ken Hillman; Kenth Johansson; Karel Kolkman; Alexander Wilmer Journal: Intensive Care Med Date: 2006-09-12 Impact factor: 17.440
Authors: Marta Martín-Llahí; Marie-Noëlle Pépin; Mónica Guevara; Fernando Díaz; Aldo Torre; Alberto Monescillo; Germán Soriano; Carlos Terra; Emilio Fábrega; Vicente Arroyo; Juan Rodés; Pere Ginès Journal: Gastroenterology Date: 2008-02-14 Impact factor: 22.682
Authors: Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber Journal: Gastroenterology Date: 2008-02-13 Impact factor: 22.682
Authors: A Ginès; A Escorsell; P Ginès; J Saló; W Jiménez; L Inglada; M Navasa; J Clària; A Rimola; V Arroyo Journal: Gastroenterology Date: 1993-07 Impact factor: 22.682
Authors: Juan Carlos Q Velez; Manish Kadian; Margarita Taburyanskaya; Nicole M Bohm; Tracie A Delay; Nithin Karakala; Don C Rockey; Paul J Nietert; Andrew J Goodwin; Timothy P Whelan Journal: Nephron Date: 2015-10-21 Impact factor: 2.847
Authors: Andrew S Allegretti; Xavier Vela Parada; Paul Endres; Sophia Zhao; Scott Krinsky; Shelsea A St Hillien; Sahir Kalim; Sagar U Nigwekar; James G Flood; Andrea Nixon; Douglas A Simonetto; Luis A Juncos; Nithin Karakala; Hani M Wadei; Kevin R Regner; Justin M Belcher; Mitra K Nadim; Guadalupe Garcia-Tsao; Juan Carlos Q Velez; Samir M Parikh; Raymond T Chung Journal: Clin Transl Gastroenterol Date: 2021-05-11 Impact factor: 4.396
Authors: A J Sanyal; T D Boyer; R T Frederick; F Wong; L Rossaro; V Araya; H E Vargas; K R Reddy; S C Pappas; P Teuber; S Escalante; K Jamil Journal: Aliment Pharmacol Ther Date: 2017-03-29 Impact factor: 8.171